Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study

Meng,Fan‑Dong; Wang,Shuai; Jiang,You‑Hong; Sui,Cheng‑Guang

doi:10.3892/mmr.2016.4754

Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study

Authors:
- Fan‑Dong Meng
- Shuai Wang
- You‑Hong Jiang
- Cheng‑Guang Sui
View Affiliations

Affiliations: Cancer Research Institute, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: January 11, 2016 https://doi.org/10.3892/mmr.2016.4754
Pages: 2124-2134

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to construct a dendritic cell (DC) vaccine transfected with a prostate-specific membrane antigen (PSMA) recombinant adenovirus and to observe the ability of the recombinant DCs in eliciting a PSMA-directed T‑cell response to prostate cancer (PCa) in vitro. Replication‑defective adenoviral vectors, were constructed using the Adxsi system. The virus titer was measured by TCID50 assay, and the expression of the PSMA gene was identified by polymerase chain reaction (PCR) generation of peripheral blood mononuclear cell (PBMC) derived DCs in vitro. In addition, a PE‑7AAD apoptosis and necrosis kit was applied to detect the survival of DCs at different MOI values to determine the optimal MOI. Morphological changes of DC were observed under a fluorescence microscope, expression of the PSMA protein was detected by western blotting 48 h after transfection, the expression of DC markers prior to and following transfection was detected by direct immunofluorescence, and the interleukin (IL)-12 concentration in the culture supernatant of the three groups was measured by ELISA. The antitumor effect of DC-stimulated cytotoxic T lymphocytes (CTLs) on different PCa cell lines was analyzed using a Cell Counting Kit‑8 assay. The optimal MOI value was determined to be 200. The PSMA protein was expressed in DCs, and the recombinant adenovirus did not impact the maturation and morphological changes of the DCs. The expression levels of the co-stimulatory molecules, CD80, CD83, CD86 and HLA‑DR, were significantly higher in the Ad‑PSMA‑DC group than in the other two groups (P<0.05). The concentration of IL‑12 in the supernatant of the Ad‑PSMA‑DC group (79.51±1.60 pg) was comparable with that of the Ad‑GFP‑DC group (not significantly different), and the two were significantly higher than the non‑transfection group (P<0.05). The optimal effector to target (E:T) ratio was determined to be 40:1. However, at the same E:T ratio, the cytotoxic activity of PSMA‑DC‑T against the LNCap cells was markedly stronger than its activity against the other target cells (DU145 and 22RV; P<0.05); furthermore, the the cytotoxic activity of PSMA-DC-T against the LNCap cells was significantly higher than the anti‑LNCap effect of DC‑T cells in other groups (P<0.05). In vitro experiments indicated that mature DCs transfected with Ad‑PSMA secreted high concentrations of IL‑12 and elicited potent antitumor immune responses targeting PSMA‑expressing cells by stimulating the cytotoxic activity of CTLs.

View Figures

View References

1	Zumwalt TH and Goel A: Immunotherapy of metastatic colorectal cancer: prevailing Challenges and new perspectives. Curr Colorectal Cancer Rep. 11:125–140. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhang H and Huang B: Tumor cell-derived microparticles: a new form of cancer vaccine. Oncoimmunology. 4:e10177042015. View Article : Google Scholar : PubMed/NCBI
3	Onji M and Akbar SMF: On dendritic cell based therapy for cancers. Zhejiang Univ Sci B. 6:1–3. 2005. View Article : Google Scholar
4	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
5	Gu F: Epidemiological survey of benign prostatic hyperplasia and prostate cancer in China. Chin Med J (Engl). 113:299–302. 2000.In Chinese.
6	Basler M and Groettrup M: Advances in prostate cancer immunotherapies. Drugs & Aging. 24:197–221. 2007. View Article : Google Scholar
7	Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, et al: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate. 38:73–78. 1999. View Article : Google Scholar : PubMed/NCBI
8	Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM and Jarisch J: Higher-dose and less frequent dendritic cellinfusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate. 43:59–62. 2000. View Article : Google Scholar : PubMed/NCBI
9	Zhou Y, Wang HP and Wang Q: Advances in design strategy of dendritic cell vaccine. Medical Journal of Chinese People's Liberation Army. 31:1205–1206. 2006.In Chinese.
10	Ribas A, Butterfield LH, Glaspy JA and Economou JS: Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2:57–78. 2002. View Article : Google Scholar : PubMed/NCBI
11	Wu Q, Xia D, Carlsen S and Xiang J: Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Curr Gene Ther. 5:237–247. 2005. View Article : Google Scholar : PubMed/NCBI
12	Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R and Rubin MA: Prostate specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 38:696–701. 2007. View Article : Google Scholar : PubMed/NCBI
13	Zhang P, Chiu YC, Tostanoski LH and Jewell CM: Polyelectrolyte multilayers assembled entirely from immune signals on gold nanoparticle templates promote antigen-specific T cell response. ACS Nano. 9:6465–6477. 2015. View Article : Google Scholar : PubMed/NCBI
14	Qiu K, Yu B, Huang H, Zhang P, Ji L and Chao H: Tetranuclear ruthenium(II) complexes with oligo-oxyethylene linkers as one-and two-photon luminescent tracking non-viral gene vectors. Dalton Trans. 44:7058–7065. 2015. View Article : Google Scholar : PubMed/NCBI
15	Xia D, Moyana T and Xiang J: Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res. 16:241–259. 2006. View Article : Google Scholar : PubMed/NCBI
16	Zhang Yan and Shen Xi: The impact of transfection with common viral vector on dendritic cells. Foreign Medical Science (Molecular Biology Section). 25:188–190. 2003.In Chinese.
17	Liu Qingxin and Song Jun: Viral vector-mediated gene therapy for prostate cancer. International Journal of Urology and Nephrology. 20:62–63. 2000.In Chinese.
18	Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP, Israel R, Scher HI and Morris S: A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 31:943–949. 2013. View Article : Google Scholar
19	Wang W and Mo ZN: Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue. 16:547–551. 2010.In Chinese. PubMed/NCBI
20	Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ and Fowler DH: Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 12:540–551. 2005. View Article : Google Scholar : PubMed/NCBI
21	Zeng H, Wu Q, Li H, Wei Q, Lu Y, Li X, Wang F, Zhao F, Ding Z and Yang Y: Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer. J Androl. 26:215–221. 2005. View Article : Google Scholar : PubMed/NCBI
22	Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ and Muruve DA: The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther. 14:627–643. 2003. View Article : Google Scholar : PubMed/NCBI
23	Philpott NJ, Nociari M, Elkon KB and Falck-Pedersen E: Adenovirus-induced maturation of dendritic cells through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Nat Acad Sci USA. 101:6200–6205. 2004. View Article : Google Scholar : PubMed/NCBI
24	Smyth MJ, Godfrey DI and Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
25	Fan Y and Moon JJ: Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines. 3:662–685. 2015. View Article : Google Scholar : PubMed/NCBI
26	Liu A, Takahashi M, Narita M, Zheng Z, Kanazawa N, Abe T, Nikkuni K, Furukawa T, Toba K, Fuse I and Aizawa Y: Generation of functional and mature dendritic cells from cord blood and bone marrow CD34+ cells by two-step culture combined with calcium ionophore treatment. J Immunol Methods. 261:49–63. 2002. View Article : Google Scholar : PubMed/NCBI
27	Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, Zhong R, Cairns E, Bell DA and Min WP: Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol. 171:691–696. 2003. View Article : Google Scholar : PubMed/NCBI
28	Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W and Blazar BR: Dendritic cells Pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 34:1403–1412. 2006. View Article : Google Scholar : PubMed/NCBI
29	Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, et al: Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol. 171:3467–3474. 2003. View Article : Google Scholar : PubMed/NCBI
30	Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, Mariani L, Camerini T, Marchianò A, Andreola S, et al: Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 9:3235–3245. 2003.PubMed/NCBI